TrialThe oncologist2021

Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.

Lorraine Pelosof et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.